# 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Source: https://onco.cc/trials/nct06079112/  
OnCo record `nct06079112` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.

## Summary

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer is a phase 1/2 interventional study registered as NCT06079112 by Mabwell (Shanghai) Bioscience Co., Ltd., with 100 participants planned, started 2023-09-27 and due to reach its primary completion in 2026-12-31. Interventions recorded: 9MW2821 and Toripalimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06079112
- Phase: 1/2
- Setting: A Phase Ib/II, Open-label, Single Arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06079112: https://clinicaltrials.gov/study/NCT06079112

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06079112.json